Data Brief 2016 Jun 12;7:654-7. Epub 2016 Mar 12.
GECKO Institute for Medicine, Informatics and Economics, Heilbronn University, Max-Planck-Str. 39, 74081 Heilbronn, Germany.
Records of female breast cancer patients were selected from a clinical cancer registry and separated into three cohorts according to HER2-status (human epidermal growth factor receptor 2) and treatment with or without Trastuzumab (a humanized monoclonal antibody). Propensity score matching was used to balance the cohorts. Afterwards, documented information about disease events (recurrence of cancer, metastases, remission of local/regional recurrences, remission of metastases and death) found in the dataset was leveraged to calculate the annual transition probabilities for every cohort.